RSV Vaccine Study - History of kidney or lung transplant

STUDY BASICS

Are you an adult age 50 or older who has had a kidney or lung transplant? You may be eligible to participate in a research study to test a new vaccine to prevent infection with the respiratory syncytial virus (RSV) in older adults (OA).  This research study involves up to 7 visits over 12 months. Compensation is provided.

STUDY PURPOSE

This study will test a vaccine that is approved by the FDA, as of May 2023, to protect older adults 60 years of age and above from respiratory syncytial virus (RSV).  The vaccine being studied in this clinical trial was made to prevent infection with the RSV in older adults (OA).  In this study, we want to find out how the body responds to RSV OA vaccine. The study will also look at the safety of the RSV OA vaccine. 

COULD THIS STUDY BE RIGHT FOR YOU?

• Adults 50 years of age and above
• History of a kidney or lung transplant

WHAT PARTICIPANTS CAN EXPECT

You will be assigned (at random) to 1 of the 2 groups

• Group 1 participants will get 1 dose of the RSV OA vaccine at Visit 1 
• Group 2 participants will get 2 doses of RSV OA vaccine, one dose at Visit 1 and the second dose between 30-60 days after the first dose.

At each visit you will have a physical exam, a blood draw and be asked questions about side effects and other medications or vaccines received.